Bayer Back In Radiopharmaceuticals Ring With Noria Buy
Adds To Targeted Alpha Therapy Pipeline
Although Bayer's radiopharmaceutical for prostate cancer Xofigo has proved a commercial disappointment, the Leverkusen-headquartered firm is keen to advance its pipeline of targeted alpha therapies, snapping up Noria and its subsidiary PSMA Therapeutics.
You may also be interested in...
"We have big plans," oncology president Susanne Schaffert said in an interview about launching Pluvicto, its new radioligand therapy for prostate cancer.
Despite the sector's woes, strong companies that generate strong patient data based on solid science have a promising future, Precirix CEO Ruth Devenyns tells Scrip.
Harvard Medical School’s Dr. Bruce Chabner, Bayer Pharma’s global head of research and Roivant Sciences founder, among others, share their views on the challenges and path ahead for KRAS inhibitors and other oncology modalities including CAR-T therapy.